[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Psychiatric University Hospital, Zurich\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":107},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100652477","treatment-with-repetitive-transcranial-magnetic-stimulation-in-peripartal-depression-100652477",false,"NCT07774559","Treatment With Repetitive Transcranial Magnetic Stimulation in Peripartal Depression","PPD and rTMS","Inclusion Criteria:\n\n* Women aged 18 years or older\n* Currently pregnant or up to 12 months after childbirth at screening\n* Current depressive episode or clinically significant depressive symptoms consistent with peripartum depression, confirmed by clinical interview according to ICD-10 criteria\n* MADRS score of at least 7 at screening\n* Able to understand German or English\n* Able to provide written informed consent\n* Willing and able to attend study visits and complete rTMS procedures, EEG and ECG recordings, hair and sputum sampling, and study questionnaires\n* Stable antidepressant and\u002For psychotherapy treatment, or no current antidepressant medication and\u002For psychotherapy; participants should agree to maintain treatment stability during the study where clinically feasible\n* Previous rTMS treatment for depression is permitted\n\nExclusion Criteria:\n\n* Current or past seizure disorder, or previous rTMS-induced seizure\n* Primary psychotic disorder\n* Acute suicidality requiring a higher level of care\n* Contraindications to rTMS, including intracranial metallic implants; implanted neurostimulators; cochlear implants; vagus nerve stimulators; ocular implants; implanted cardiac electrodes or pacemakers; aneurysm coils or clips; ventriculo-peritoneal shunts; or other ferromagnetic or electronic implants in the head or neck\n* Clinically significant head injury within the previous 12 months or with relevant residual symptoms\n* Unstable or severe medical or obstetric complications that could make participation unsafe, such as preeclampsia or imminent preterm labour requiring intensive management\n* Severe substance use disorder that could interfere with safety or study assessments\n* Inability to follow study procedures, for example because of cognitive impairment\n* Frequent severe migraine, including chronic migraine with status migrainosus, if high-frequency rTMS is considered likely to worsen symptoms, unless the investigator and treating physician determine that participation is safe.","FEMALE","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn whether repetitive transcranial magnetic stimulation (rTMS) can reduce depressive symptoms in women who are pregnant or up to 12 months after childbirth and have peripartum depression. rTMS is a non-invasive treatment in which a device placed on the scalp delivers gentle magnetic pulses to a brain area involved in mood regulation. It does not involve medication or anaesthesia.\n\nThe main questions this study aims to answer are:\n\n* Does active rTMS reduce depressive symptoms more than sham rTMS?\n* What side effects occur during treatment, and how well is rTMS tolerated?\n* Are improvements in depressive symptoms still present one month after treatment?\n\nResearchers will compare active rTMS with sham rTMS, a treatment designed to feel and sound similar but not to provide effective brain stimulation. Neither participants nor the clinicians assessing depressive symptoms will know which treatment was assigned during the main study phase.\n\nUp to 60 women aged 18 years or older who are pregnant or up to 12 months after childbirth and have clinically relevant depressive symptoms may take part. Participants will:\n\n* Attend a screening and baseline visit, including questionnaires, EEG and ECG recordings, and collection of small hair and sputum samples to study stress-related hormone levels\n* Be assigned by chance to receive either active rTMS or sham rTMS\n* Attend 30 treatment sessions, scheduled flexibly over approximately 1.5 to 10 weeks to accommodate childcare, breastfeeding, fatigue, and medical appointments\n* Complete questionnaires about mood, wellbeing, quality of life, social support, and treatment expectations before and after treatment\n* Have safety and side effects checked before each treatment session\n* Complete a telephone follow-up assessment one month after treatment\n* Be asked to complete a short questionnaire about their child's development one year after treatment\n\nEach treatment visit lasts about 30 minutes, including preparation, treatment, and a short safety check. Infants may be brought to treatment visits when this can be done safely.\n\nrTMS is generally well tolerated. Possible temporary side effects include headache, scalp discomfort, facial muscle twitching during stimulation, dizziness, or tiredness. A seizure is a very rare but serious possible risk; therefore, people with epilepsy, certain implants, or other relevant risk factors cannot take part.\n\nParticipation is voluntary. Participants can pause or stop participation at any time without affecting their usual care. Personal data will be coded and handled confidentially. Women assigned to sham treatment will be offered active rTMS after the blinded study phase, if they wish. The results may help clarify whether rTMS is an effective non-medication treatment option for peripartum depression.",[26,27,28],"Depression During Pregnancy","Postpartum Depression (PPD)","Peripartum Depression",[30,31,32,33,34,35],"Peripartal depression","Postpartal depression","Antenatal depression","Repetitive transcranial magnetic stimulation","Transcranial magnetic stimulation","rTMS","NOT_YET_RECRUITING","2026-08-17",{"date":39,"type":40},"2026-08-19","ACTUAL",{"date":42,"type":20},"2026-09",{"date":44,"type":20},"2030-08-31",{"name":46,"class":47},"Psychiatric University Hospital, Zurich","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":17,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100647478","virtual-reality-exposure-therapy-for-emotion-regulation-difficulties-in-adolescent-inpatients-100647478","NCT07709468","Virtual Reality Exposure Therapy for Emotion Regulation Difficulties in Adolescent Inpatients","Investigating the Efficacy of a Virtual Reality Exposure Therapy Intervention Targeting Emotion Regulation Difficulties in Adolescent Inpatients","VRsafe","Inclusion Criteria:\n\n* Written informed consent\u002Fassent.\n* Age 11-18 years.\n* Intelligence Quotient (IQ) ≥ 85.\n* Ability and willingness to participate in VR procedures, behavioral tasks, and questionnaires.\n\nExclusion Criteria:\n\n* Major somatic or cardiovascular conditions.\n* Aggressive behavior posing a risk to self or others.\n* Participation in another clinical investigation within the previous 30 days.\n* Severe motion sickness or vestibular disorders.\n* Inability to comply with study procedures.\n* Discharge from the inpatient setting before completing the minimum intervention duration.",true,"ALL","11 Years",{"count":61,"type":20},90,[23],"The goal of this clinical trial is to evaluate whether a therapist-guided virtual reality (VR)-based intervention can improve emotion regulation in adolescents receiving inpatient psychiatric treatment. The study will also assess the feasibility, acceptability, and safety of the intervention, as well as explore factors that may predict treatment response.\n\nThe main questions it aims to answer are:\n\nDoes the VR-based intervention improve emotion regulation compared with a VR relaxation control intervention? Does the intervention reduce sensory sensitivities, anxiety, and related psychological symptoms? Which behavioral, physiological, and speech-based measures are associated with treatment response?\n\nResearchers will compare a personalized VR exposure intervention with a VR relaxation control intervention. Both groups will receive treatment as usual during their inpatient stay.\n\nParticipants will:\n\nBe randomly assigned to either the VR exposure or the VR relaxation group. Complete questionnaires, behavioral tasks, and clinical assessments before and after the intervention, with a follow-up assessment approximately three months later.\n\nParticipate in weekly therapist-guided VR sessions throughout their inpatient treatment.\n\nComplete additional assessments including speech recordings and standardized behavioral tasks to investigate predictors and mechanisms of treatment response.\n\nThroughout the study, participants will be monitored for adverse events and tolerability of the VR intervention.",[65],"Emotion Regulation Disorders",[67,68,69,70,71,72,73,74,75],"Virtual Reality","Virtual Reality Exposure Therapy","Emotion Regulation","Adolescents","Child and Adolescent Psychiatry","Inpatient Psychiatry","Anxiety Disorders","Social Anxiety","Sensory Sensitivity \u002F Sensory Over-Responsivity","2026-07-13",{"date":78,"type":40},"2026-07-16",{"date":80,"type":20},"2026-08-04",{"date":82,"type":20},"2030-10",{"name":46,"class":47},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":58,"minAge":17,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":48},"100482326","digital-self-efficacy-training-to-bridge-waiting-times-for-psychotherapy-100482326","NCT05560581","Digital Self-efficacy Training to Bridge Waiting Times for Psychotherapy","Inclusion Criteria:\n\n* psychiatric disorder\n* age 18-65\n* waiting for psychiatric assessment\u002Ftreatment (being on waitlist)\n* sufficient knowledge of the German language\n* smartphone user\n* internet access via smartphone\n* internet access at home (laptop, tablet, or computer)\n\nExclusion Criteria:\n\n* current intense psychotherapy\n* acute suicidality\n* acute psychotic symptoms\n* substance addiction","65 Years",{"count":92,"type":20},94,[23],"The main aim of this project is to improve waiting periods for specialised psychotherapy. We will apply a brief, smartphone-based self-efficacy training to patients with psychiatric disorders waiting for specialised psychotherapy. Additionally, we will use Ecological Momentary Assessment (EMA) to assess mood, social contacts, and other parameters daily. We will investigate whether the training can improve self-efficacy and related constructs and if it can help reduce stress and waitlist drop-outs during waiting periods. Additionally, we will investigate if the self-efficacy training has a positive effect on motivation and therapeutical relationship regarding the subsequent therapy.\n\nAfter a screening for eligibility, participants will be randomly assigned to intervention and control group. At baseline, participants attend a laboratory session where they are assessed for current psychiatric disorders and further relevant psychological variables. They will then either participate in the digital self-efficacy training combined with EMA (intervention group) or in EMA only (control group). Both will be conducted via a smartphone app. Subsequently, participants will be asked to fill in post questionnaires at three different time points: after having finished app usage, one month later, and after the beginning of the subsequent psychotherapy.",[96,97],"Psychiatric Disorder","Waiting for Psychotherapy","RECRUITING","2025-02-27",{"date":101,"type":40},"2025-03-04",{"date":103,"type":40},"2022-11-07",{"date":105,"type":20},"2025-11",{"name":46,"class":47},""]